SCHEDULE: Pelthos Therapeutics Updates Ownership Post-Merger and PIPE Financing, Reveals Key Shareholder Stakes

Pelthos Therapeutics Inc. has filed an amended Schedule 13D, detailing updated beneficial ownership stakes for Ezra Friedberg, Balmoral Financial Group LLC, and Key Recovery Group LLC following a reverse stock split, a merger, and a private investment in public equity (PIPE) financing.

Summary

• The filing is Amendment No. 1 to the Schedule 13D originally filed on February 26, 2024, by Ezra Friedberg, Balmoral Financial Group LLC, and Key Recovery Group LLC.
• The reported share numbers have been adjusted to reflect a 1-for-10 reverse stock split effected by Pelthos Therapeutics Inc. on July 1, 2025.
• Ezra Friedberg, a director of Pelthos Therapeutics Inc. and manager of Balmoral and Key, beneficially owns an aggregate of 250,121 shares of Common Stock, representing 8.3% of the class.
• Mr. Friedberg's beneficial ownership includes 186,645 shares acquired with personal funds and 63,476 shares from stock options awarded in his capacity as a director.
• Balmoral Financial Group LLC beneficially owns 92,072 shares, representing 3.1% of the class.
• Key Recovery Group LLC beneficially owns 40,000 shares, representing 1.3% of the class.
• The beneficial ownership percentages are calculated based on 3,034,416 shares of Common Stock outstanding as of July 2, 2025.
• On April 16, 2025, Pelthos Therapeutics Inc. entered into a Merger Agreement with CHRO Merger Sub Inc. and LNHC, which was completed on July 1, 2025, resulting in LNHC becoming a wholly-owned subsidiary and the combined company operating as Pelthos Therapeutics Inc.
• In connection with the Merger Agreement, Balmoral and Key participated in a PIPE Financing on April 16, 2025, purchasing 400 shares of Series A Preferred Stock each for $400,000 per entity, with the financing closing on July 1, 2025.
• Each share of Series A Preferred Stock is convertible into 100 shares of Common Stock (post-reverse split), and Balmoral and Key immediately converted their 400 shares of Series A Preferred Stock into 40,000 shares of Common Stock each upon closing.
• A Registration Rights Agreement was entered into on July 1, 2025, obligating Pelthos to register for resale certain shares held by PIPE investors, including those issued in the Merger and PIPE Financing.
• A Lock-Up Agreement was also executed, restricting certain stockholders, directors, and executive officers, including Ligand, from selling or transferring shares from the Merger closing until December 31, 2025, with limited exceptions.

Sentiment

Score: 7

Explanation: The document reports the successful completion of significant corporate actions (merger, PIPE financing, reverse stock split) which are generally positive for a company's strategic development and financial stability. While a 13D/A is primarily factual, the successful execution of these plans indicates progress.

Positives

• Completion of the Merger Agreement with LNHC, consolidating operations under Pelthos Therapeutics Inc., indicates strategic growth and integration.
• Successful closing of the PIPE Financing, with Balmoral and Key contributing $800,000 in total, provides capital to the company.
• The immediate conversion of Series A Preferred Stock into Common Stock by Balmoral and Key demonstrates their commitment and confidence in the company's equity.

Risks

• The Lock-Up Agreement restricts certain stockholders, directors, and executive officers from selling shares until December 31, 2025, which could lead to increased selling pressure once the lock-up period expires.
• The Issuer is obligated to file a resale registration statement for certain shares, which, once effective, could increase the float and potentially dilute existing shareholder value if a large volume of shares are sold.

Future Outlook

Pelthos Therapeutics Inc. is obligated to prepare and file a resale registration statement with the SEC for certain shares of Common Stock and Series A Preferred Stock held by PIPE investors. This statement is to be filed on or prior to the later of 30 days following the PIPE Financing closing or 15 calendar days after the due date of the next periodic report, with reasonable best efforts to achieve effectiveness within 120 calendar days (or 150 days if reviewed by the SEC).

Industry Context

This filing reflects a common set of corporate actions in the biotechnology or pharmaceutical industry, where companies often undergo mergers, reverse stock splits, and private placements to restructure, raise capital, and integrate new assets or pipelines. The completion of a merger and associated financing is a significant step for a company like Pelthos Therapeutics Inc., indicating a strategic shift and potentially new operational focus following the integration of LNHC.

Comparison to Industry Standards

• The 1-for-10 reverse stock split is a common mechanism used by companies, particularly in the biotech sector, to increase share price and meet listing requirements or improve market perception, similar to actions taken by companies like Sorrento Therapeutics or Athersys in the past.
• PIPE financings are standard capital-raising tools for public companies, especially smaller biotechs, to secure funding quickly from institutional or accredited investors, comparable to recent PIPE deals seen with companies such as BridgeBio Pharma or Recursion Pharmaceuticals.
• Lock-up agreements are typical in mergers and private placements to prevent immediate selling pressure from insiders or large investors post-transaction, aligning with practices observed in numerous M&A transactions across various industries, including those involving biotech firms like BioNTech or Moderna post-IPO/major financing rounds.

Corporate Governance

Related Party Transactions

• Ezra Friedberg, a director of Pelthos Therapeutics Inc., serves as the manager of Balmoral Financial Group LLC and Key Recovery Group LLC. Both Balmoral and Key participated in the PIPE Financing, purchasing Series A Preferred Stock from the Issuer, making this a related party transaction.

Stakeholder Impact

• Shareholders: The reverse stock split reduces the number of outstanding shares, potentially increasing the per-share price. The merger and PIPE financing could enhance the company's strategic position and financial health. The registration rights agreement may lead to future dilution if registered shares are sold, while the lock-up agreement temporarily restricts insider selling.
• Investors (PIPE): Balmoral and Key, as PIPE investors, have gained significant equity stakes and have registration rights to facilitate future liquidity.

Next Steps

• Pelthos Therapeutics Inc. will prepare and file a resale registration statement with the SEC for certain shares of Common Stock and Series A Preferred Stock held by PIPE investors.
• The Issuer will use reasonable best efforts to cause this registration statement to be declared effective by the SEC within 120 calendar days of the PIPE Financing closing (or 150 calendar days if the SEC reviews it).

Key Dates

Keywords

Pelthos Therapeutics Inc., Schedule 13D/A, beneficial ownership, reverse stock split, merger, PIPE financing, Ezra Friedberg, Balmoral Financial Group, Key Recovery Group, Series A Preferred Stock, Common Stock, Registration Rights Agreement, Lock-Up Agreement, corporate governance, SEC filing